11.01.23
IQVIA
3Q Revenues: $3.7 billion (+5%)
3QEarnings: $303 million (+7%)
YTD Revenues: $11.1 billion (+4%)
YTD Earnings: $889 million (+3%)
Comments: Technology & Analytics Solutions (TAS) revenue was $1.4 billion, up 2% in the quarter. Research & Development Solutions (R&DS) revenue was $2.1 billion, up 7%. Contract Sales & Medical Solutions (CSMS) revenue was flat at $183 million.
At the end of the quarter, R&DS contracted backlog, including reimbursed expenses, was $28.8 billion, up 11.7 percent year-over-year. The company expects approximately $7.4 billion of this backlog to convert to revenue in the next twelve months. The third-quarter book-to-bill ratio was 1.24x. For the twelve months ended September 30, 2023, the book-to-bill ratio was 1.33x.
3Q Revenues: $3.7 billion (+5%)
3QEarnings: $303 million (+7%)
YTD Revenues: $11.1 billion (+4%)
YTD Earnings: $889 million (+3%)
Comments: Technology & Analytics Solutions (TAS) revenue was $1.4 billion, up 2% in the quarter. Research & Development Solutions (R&DS) revenue was $2.1 billion, up 7%. Contract Sales & Medical Solutions (CSMS) revenue was flat at $183 million.
At the end of the quarter, R&DS contracted backlog, including reimbursed expenses, was $28.8 billion, up 11.7 percent year-over-year. The company expects approximately $7.4 billion of this backlog to convert to revenue in the next twelve months. The third-quarter book-to-bill ratio was 1.24x. For the twelve months ended September 30, 2023, the book-to-bill ratio was 1.33x.